Anesthesiology and Intensive Care Department, Pomeranian Medical University, Szczecin, Poland.
Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6843-6849. doi: 10.26355/eurrev_202307_33155.
Subarachnoid hemorrhage (SAH) causes a high percentage of deaths and rehabilitation failures. Despite endovascular and surgery treatment algorithms, there is still no consensus on the guidelines for monitoring and neuroprotective treatment of patients.
We report a case of a patient with SAH treated endovascularly. The patient was hospitalized in the intensive care unit and monitored using Near Infrared Spectroscopy (NIRS) and Optic Nerve Diameters Assessment (ONDS).
Early and high-dose Cerebrolysin was used safely as neuroprotective treatment intravenously. The treatment using Cerebrolysin and additional monitoring was beneficial for the patient.
蛛网膜下腔出血 (SAH) 导致高比例的死亡和康复失败。尽管有血管内和手术治疗方案，但对于患者的监测和神经保护治疗指南仍未达成共识。
我们报告了一例接受血管内治疗的 SAH 患者。该患者住院于重症监护病房，使用近红外光谱 (NIRS) 和视神经直径评估 (ONDS) 进行监测。
早期和高剂量的脑活素作为神经保护治疗，安全地静脉内使用。使用脑活素和额外监测的治疗对患者有益。
